Despite being introduced to the European market eight years ago and the U.S. market four years ago, transcatheter aortic valve replacement (TAVR) sales are still delivering impressive results for Edwards Lifesciences Corp. (Irvine, Calif.) and adoption doesn't appear to be slowing down any time soon. After the market closed Tuesday, Edwards released fourth-quarter earnings that showed a 25-percent increase in TAVR sales and raised its full-year earnings forecast. Read More
